

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
1002100 10/528021 2005 APR 22 2005 CT

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/528,021
Filing Date	03-16-2005
First Named Inventor	Francis-Lang
Art Unit	
Examiner Name	
Total Number of Pages in This Submission	23
Attorney Docket Number	EX03-067C-US

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	Exelixis, Inc.		
Signature			
Printed Name	Laleh Shayesteh		
Date	April 20, 2005	Reg. No.	47,937

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.


Signature			
Typed or printed name	Laleh Shayesteh	Date	April 20, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

App. No. 10/528,021

Docket No. EX03-067



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Francis-Lang, *et al.*

Application No.: 10/528,021

Filed: March 16, 2005

For: PAKS AS MODIFIERS OF THE CHK
PATHWAY AND METHODS OF USE

Confirmation no.: 1018

Attorney Docket No.: EX03-067C-US

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In accordance with 37 CFR §1.56, this Information Disclosure Statement is being submitted for the above-referenced application.

In accordance with §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined by 37 CFR §1.56 exists.

In accordance with §1.97(h), the disclosure contained herein is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" or "analogous art" for this invention.

It is believed that no fees are required for the submission of this IDS. However, if this belief is in error, the Commissioner is authorized to charge any required fees to deposit account no. 50-1108.

Respectfully submitted,

Dated: April 20, 2005

Latch Shoyesteh Reg. No. 47,937
Tel: (650) 837-8223; Fax: (650) 837-8234



App. No. 10/528,021

Docket No. EX03-067C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Francis-Lang, *et al.*

Application No.: 10/528,021

Filed: March 16, 2005

For: PAKS AS MODIFIERS OF THE CHK
PATHWAY AND METHODS OF USE

Confirmation No.: 1018

Attorney Docket No.: EX03-067C-US

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The GENESEQ® database was queried to identify sequences that are identical or related to the sequences recited in the claims of the above-referenced patent application. The following patent publications were identified:

WO02081638, ORIGENE TECHNOLOGIES INC, 2002-10-17

WO0060062, ASTRAZENECA UK LTD, 2000-10-12

WO9953036, SUGEN INC, 1999-10-21

The above-references have **not** been reviewed to assess whether they are material to the patentability of the claimed invention; nor have they been reviewed to assess whether they are substantively cumulative to the disclosures of the references cited in and provided with the "Information Disclosure Statement by Applicant" filed simultaneously herewith.

Upon request, Applicants will gladly obtain copies of any of these references and forward them to the Examiner for consideration.

Respectfully submitted,

Dated: April 20, 2005

Laleh Shayesteh

Reg. No. 47,937

Tel: (650) 837-8223; Fax: (650) 837-8234



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/528,021
Filing Date	March 16, 2005
First Named Inventor	Francis-Lang
Art Unit	
Examiner Name	
Attorney Docket Number	EX03-067C-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Schraml, P., et al. Homo sapiens p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) (PAK1), mRNA. Genbank GI:7382495	
	2	NCBI Annotation Project. Homo sapiens p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) (PAK1), mRNA. Genbank GI:20483033	
	3	Reid, T., et al. Homo sapiens p21 activated kinase 1B (PAK1B) mRNA, complete cds. Genbank GI:3265159	
	4	Ota, T., et al. Homo sapiens cDNA FLJ30666 fis, clone FCBBF1000627, highly similar to SERINE/THREONINE-PROTEIN KINASE PAK-ALPHA (EC 2.7.1.-). Genbank GI:16549911	
	5	Brown, J.L., et al. Human protein kinase PAK1 mRNA, complete cds. Genbank GI:1256421	
	6	NCBI Annotation Project. Homo sapiens p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) (PAK1), mRNA. Genbank GI:18577341	
	7	Schraml, P., et al. p21-activated kinase 1; p21/Cdc42/Rac1-activated kinase 1 (yeast Ste20-related) [Homo sapiens]. Genbank GI:7382496	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.